Why the study?
Does discontinuation of clopidogrel increase the risk of adverse clinical events in patients with acute coronary syndromes or post-PCI?
Population
Patients with acute coronary syndromes or those who have undergone percutaneous coronary intervention (PCI)
Design
Systematic_review
Authors
Loading...
May warrant caution against early clopidogrel discontinuation post-PCI; leaves open confirmation from randomized trials.
Does discontinuation of clopidogrel increase the risk of adverse clinical events in patients with acute coronary syndromes or post-PCI?
Premature or perioperative discontinuation of clopidogrel post-PCI or in ACS appears to increase the risk of adverse cardiac events, particularly in the first 1-6 months, though evidence is limited by the lack of randomized trials.
Gaglia et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: